Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

553
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
553
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

413
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
413
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

817
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
817
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

808
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
808
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

510
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
510
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

1.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

G-protein regulatory network governs receptor internalization dynamics.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Lac-Phe elicits anxiolytic-like effects associated with monoaminergic signaling in mice.

Translational psychiatry·2026
Same author

An RYR2-interacting fragment of MYBPC3 mitigates arrhythmia in human iPSC-CM and mouse models of CPVT.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

GPR3 Ligands Discovered through Combined Virtual and Conformational Biosensor-Based Screening.

Journal of the American Chemical Society·2026
Same author

Rapid functional classification of cardiac genetic variants directly informs precision cardiology.

bioRxiv : the preprint server for biology·2026
Same author

Phosphorylation site topology governs the functional dynamics of arrestin recruitment to GPCRs.

Research square·2026

Related Experiment Video

Updated: Aug 20, 2025

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
07:51

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

28.7K

How Carvedilol activates β2-adrenoceptors.

Tobias Benkel1,2, Mirjam Zimmermann3, Julian Zeiner1

  • 1Molecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115, Bonn, Germany.

Nature Communications
|November 19, 2022
PubMed
Summary
This summary is machine-generated.

Carvedilol

More Related Videos

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.7K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

590

Related Experiment Videos

Last Updated: Aug 20, 2025

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
07:51

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

28.7K
Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.7K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

590

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Carvedilol improves survival post-myocardial infarction, but its precise mechanisms remain unclear.
  • Existing hypotheses suggest arrestin-biased signaling via beta-2 adrenoceptors (β2ARs) contributes to its benefits.
  • Understanding drug mechanisms is crucial for clinical applications and research.

Purpose of the Study:

  • To investigate the molecular signaling mechanisms underlying carvedilol's effects.
  • To determine the role of G proteins versus arrestins in β2AR signaling by carvedilol.
  • To provide a mechanistic basis for developing novel cardiovascular therapeutics.

Main Methods:

  • Utilized CRISPR/Cas9 genome-edited cells lacking G proteins or arrestins.
  • Employed a combination of biological, biochemical, and signaling assays.
  • Incorporated molecular dynamics simulations to analyze drug-target interactions.

Main Results:

  • Demonstrated that G proteins, not arrestins, mediate all detectable carvedilol signaling through β2ARs.
  • Challenged the prevailing hypothesis of arrestin-biased signaling for carvedilol's effects.
  • Provided definitive evidence for the G protein-dependent pathway of carvedilol action.

Conclusions:

  • Carvedilol's cellular signaling is driven by G proteins acting through β2ARs.
  • This finding offers an alternative mechanistic explanation for carvedilol's clinical efficacy.
  • The gained mechanistic insight can guide the rational design of new drugs targeting the β-adrenoceptor system.